Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 16/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24377969 | 0.92 | SIRT1 (0.50) | SIRT1POLBSIRT2SIRT3 | |
| SCHEMBL26938749 | 0.89 | POLB (0.44) | SIRT1POLBUSP30TP53GAA | |
| SCHEMBL24377971 | 0.86 | SIRT1 (0.43) | SIRT1POLBSIRT2SIRT3 | |
| SCHEMBL24377972 | 0.84 | BRD4 (0.42) | SIRT1SIRT2SIRT3 | |
| SCHEMBL26938829 | 0.83 | SIRT1 (0.65) | SIRT1SIRT2SIRT3 | |
| SCHEMBL24378125 | 0.83 | SIRT1 (0.65) | SIRT1SIRT2SIRT3 | |
| SCHEMBL24378118 | 0.83 | SIRT1 (0.65) | SIRT1SIRT2SIRT3 | |
| SCHEMBL24378122 | 0.83 | TP53 (0.49) | SIRT1POLBTP53GAA | |
| SCHEMBL24377993 | 0.83 | SIRT1 (0.49) | SIRT1POLBSIRT2SIRT3 | |
| SCHEMBL29516214 | 0.83 | SIRT1 (0.49) | SIRT1POLBSIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | SIRT1 935/4885POLB 2308/4885SIRT2 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.